


PHARMACEUTICAL 2023

Eterna Therapeutics Inc. Rank 317 of 446









PHARMACEUTICAL 2023



Eterna Therapeutics Inc. Rank 317 of 446

The relative strengths and weaknesses of Eterna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eterna Therapeutics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Eterna Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is -23%, being 66% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,681
Cost of Goods Sold	0
Intangible Assets	2,044
Liabilities, Current	7,654
Liabilities, Non-Current	981
Other Assets	6,318
Other Compr. Net Income	0
Other Expenses	6,035
Other Liabilities	1,537
Other Net Income	8,683
Other Revenues	0
Property and Equipment	236
Research and Development	10,392
Selling, General and Administrative Expense	16,835

Output Variable	Value in 1000 USD
Assets	22,279
Liabilities	10,172
Expenses	33,262
Revenues	0
Stockholders Equity	12,107
Net Income	-24,579
Comprehensive Net Income	-24,579
Economic Capital Ratio	-23%

